• 1
    Kaufman DB. Pancreas transplantation. In: StuartFP, AbecassisMM, KaufmanDB, eds. Organ Transplantation. Texas: Landes Bioscience, 2000: 145.
  • 2
    Di Carlo A, Odorico JS, Leverson GE, et al. Long-term outcomes in simultaneous pancreas-kidney transplantation: lessons relearned. Clin Transpl 2003: 215.
  • 3
    Tyden G, Bolinder J, Solders G, et al. Improved survival in patients with insulin-dependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. Transplantation 1999; 67: 645.
  • 4
    Smets YF, Westendorp RG, Van Der Pijl JW, et al. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet 1999; 353: 1915.
  • 5
    Ojo AO, Meier-Kriesche HU, Hanson JA, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001; 71: 82.
  • 6
    Becker BN, Brazy PC, Becker YT, et al. Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int 2000; 57: 2129.
  • 7
    Schulz T, Heimes M, Schindler A, Busing M. TAC/MMF/Pred/single shot ATG versus CsA/MMF/Pred single shot ATG after pancreas-/kidney transplantation (PNTX) – initial results of a prospective randomized study. Langenbecks Arch Chir Suppl Kongressbd 1998; 115(Suppl. I): 141.
  • 8
    Steurer W, Bonatti H, Obrist P, et al. Incidence of intraabdominal infection (Iai). In a consecutive series of 40 enteric drained pancreas transplants with Fk506 and Mmf immunosuppression. Transplant int 2000; 13 (Suppl. 1): 195.
  • 9
    Linhares MM, Gonzalez AM, Trivino T, et al. Simultaneous pancreas-kidney transplantation: infectious complications and microbiological aspects. Transplant Proc 2004; 36: 980.
  • 10
    Bonatti H, Berger N, Kafka R, et al. Experience with ATG short course high dose induction therapy in a series of 112 enteric drained pancreatic transplants. Ann Transplant 2002; 7: 22.
  • 11
    Yussim A, Shapira Z. Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation – a prospective, randomized study. Transpl Int 2000; 13 (Suppl. 1): S293.
  • 12
    Pirsch JD, Odorico JS, D'Alessandro AM, Knechtle SJ, Becker BN, Sollinger HW. Posttransplant infection in enteric versus bladder-drained simultaneous pancreas-kidney transplant recipients. Transplantation 1998; 66: 1746.
  • 13
    Smets YF, Van Der Pijl JW, Van Dissel JT, Ringers J, De Fijter JW, Lemkes HH. Infectious disease complications of simultaneous pancreas kidney transplantation. Nephrol Dial Transplant 1997; 12: 764.
  • 14
    Lumbreras C, Fernandez I, Velosa J, Munn S, Sterioff S, Paya CV. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 1995; 20: 514.
  • 15
    Ronco C, Chiaramonte S, Remuzzi G, eds. Kidney Transplantation: Strategies to Prevent Organ Rejection. Monitoring of Immunosuppressive Therapy in Renal Transplanted Patients, Vol. 146. Karger: Contrib Nephrol. Basel, 2005.
  • 16
    Steurer W, Margreiter R, Königsrainer A. Surgical techniques of pancreas transplantation. Acta Chirurgica Austriaca 2001; 33: S8.
  • 17
    Sutherland DER, Cecka M, Gruessner A. Newsletter from the International Pancreas Transplant Registry, 2001.
  • 18
    Vincenti F, Stock P. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. Transplant Proc 2003; 35 (Suppl. 3): 183S.
  • 19
    Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int 2006; 19: 2.
  • 20
    Garbino J, Lorenzi P, Morel P, Romand JA. Kidney and pancreas transplantation: postoperative infectious complications. Clin Microbiol Infect 1999; 5: 48.
  • 21
    Bonatti H, Königsrainer A, Allerberger F, Riedmann B, Margreiter R, Steurer W. How to treat graft infection after pancreas transplantation. Transpl Proc 1995; 27: 3045.
  • 22
    Bonatti H, Steurer W, Konigsrainer A, Allerberger F, Margreiter R. Infection of the pancreatic duct following pancreas transplantation with bladder drainage. J Chemother 1995; 7: 442.
  • 23
    Troppmann C, Gruessner AC, Dunn DL, Sutherland DE, Gruessner RW. Surgical complications requiring early relaparotomy after pancreas transplantation: a multivariate risk factor and economic impact analysis of the cyclosporine era. Ann Surg 1998; 227: 255.
  • 24
    Kusne K, Chakrabarti P, Akhavan-Heidari M, Corry RJ. Association of bacterial and fungal infections with surgical complications in pancreas transplant recipients. Transplantation 1999; 67: S174.
  • 25
    Jorgensen KA, Dieperink H, Kirkegaard P. Complications of immunosuppressive therapy in organ transplantation. Ugeskr Laeger 2003; 165: 4727.
  • 26
    Hafiz MM, Poggioli R, Caulfield A, et al. Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus. Am J Transplant 2004; 4: 1697.
  • 27
    Stratta RJ, Gaber AO, Shokouh-Amiri MH, Reddy KS, Egidi MF, Grewal HP. Allograft pancreatectomy after pancreas transplantation with systemic-bladder versus portal-enteric drainage. Clin Transplant 1999; 13: 465.
  • 28
    Wakelin SJ, Casey J, Robertson A, et al. The incidence and importance of bacterial contaminants of cadaveric renal perfusion fluid. Transpl Int 2005; 17: 680.
  • 29
    Bucher P, Oberholzer J, Bosco D, et al. Microbial surveillance during human pancreatic islet isolation. Transpl Int 2005; 18: 584.
  • 30
    Odorico JS, Heisey DM, Voss BJ, et al. Donor factors affecting outcome after pancreas transplantation. Transpl Proc 1998; 30: 276.
  • 31
    Bindi ML, Biancofiore G, Meacci L, et al. Early morbidity after pancreas transplantation. Transpl Int 2005; 18: 1356.
  • 32
    Stratta RJ, Lo A, Shokouh-Amiri MH, Egidi MF, Gaber LW, Gaber AO. Improving results in solitary pancreas transplantation with portal-enteric drainage, thymoglobin induction, and tacrolimus/mycophenolate mofetil-based immunosuppression. Transpl Int 2003; 16: 154.
  • 33
    Friend PJ. Trends in organ preservation. Transpl Int 2003; 16: 701.